Alumis (ALMS) Revenue & Revenue Breakdown
Alumis Revenue Highlights
Latest Revenue (Y)
$24.05M
Latest Revenue (Q)
$1.74M
Main Segment (Y)
License
Alumis Revenue by Period
Alumis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $24.05M | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | - |
Alumis generated $24.05M in revenue during NA 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Alumis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $1.74M | -9.75% |
| 2025-12-31 | $1.93M | -6.63% |
| 2025-09-30 | $2.07M | -22.51% |
| 2025-06-30 | $2.67M | -84.67% |
| 2025-03-31 | $17.39M | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | - |
Alumis generated $1.74M in revenue during Q1 2026, up -9.75% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Alumis Revenue Breakdown
Alumis Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 |
|---|---|
| Collaboration Revenue | $6.66M |
| License | $17.39M |
Latest
Alumis's latest annual revenue breakdown by segment (product or service), as of Dec 25: License (72.30%), and Collaboration Revenue (27.70%).
Quarterly Revenue by Product
| Product/Service | Mar 26 | Dec 25 | Sep 25 | Jun 25 |
|---|---|---|---|---|
| Collaboration Revenue | $1.74M | $1.93M | $2.07M | $2.67M |
| License | - | - | $17.39M | $17.39M |
Latest
Alumis's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Collaboration Revenue (100.00%).
Alumis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ETON | Eton Pharmaceuticals | $79.95M | $24.27M |
| ADCT | ADC Therapeutics | $73.55M | $20.85M |
| BCYC | Bicycle Therapeutics | $72.59M | $887.00K |
| LXRX | Lexicon Pharmaceuticals | $49.80M | $21.10M |
| ALMS | Alumis | $24.05M | $1.74M |
| OCGN | Ocugen | $4.41M | $1.53M |
| RAPT | RAPT Therapeutics | - | - |
| FULC | Fulcrum Therapeutics | - | - |
| NMRA | Neumora Therapeutics | - | - |
| OMER | Omeros | - | - |